For Cynthia-ga. Could you provide me with any recent sales of medical
device companies in the last 6-12 months, what their annual gross
income was, sales price and parties involved? Extra tip for any
companies bought by Allergan

---

Request for Question Clarification by cynthia-ga on 09 Feb 2005 07:47 PST

Hi 11boomer,

I have a computer problem that requires my attention for the next day,
maybe two.  After it's fixed, I'll give it a go.  I popped in to check
if anyone was looking for me  ;-)  --so I could reply in a timely
manner...  As before, if I'm not able to find the information you
seek, I'll post _that_, so other researchers can search for you.

~~Cynthia

---

Request for Question Clarification by cynthia-ga on 20 Feb 2005 09:36 PST

11boomer,

When I reread your question, it occurred to me that my best friend
works for "Medtronic - Physio-Control" in Redmond WA.  I'm about 15
miles away in Seattle.  She had been telling me for months that
something "was happening" and she couldn't talk about it.  I HATE
THAT, --but *IT* finally happened.  The company was aquired by another
company, about 3 months ago, I didn't pay attention to the name when
she told me because in Seattle, no matter who owns them, they are
ALWAYS Physio-Control.  Physio-Control makes the LIFEPAK
Defibrillators, among other things, and they are very well known here,
and very respected.  They sell a home model defib through Wahlgreens.
Their stock just split.  I can find their financials and possibly the
principals involved.

If this is the type of information you need, let me know, and I'll
call her when she gets home tonight.  She may have Industry magazines
I can peruse for news, or she might know of other recent aquisitions.

Medtronics aquired Physio-Control in 1998, so when you type in
http://www.physio-control.com/ -- This comes up: 
http://www.medtronic-ers.com/


I'll search the internet again, but she is my best lead for information.


A quick search on the net turned up this, so far:


Some older aquisitions here:

Medical Devices News
http://www.medical-devices-faraday.com/news_industry.html
Current News:  http://www.medical-devices-faraday.com/news_industry.html
(nothing there for you right now)

Such as:

MEDEX - December 6, 2004 - 1 Billion
http://www.medex.com/medex/home.aspx
..."Medex, Inc. today announced that Smiths Group plc, a UK based
manufacturer has agreed to acquire privately-held Medex in a
transaction which will greatly enhance the global presence of Smiths
Medical for devices used in critical care..."


Some Industry News:

Device R&D Outsourcing
http://www.mpo-mag.com/Oct031.htm
..."Growth Spurs R&D Needs - According to Frost & Sullivan, the $55
billion U.S. device market is expected to grow about 10% annually for
the next couple of years to reach $74.5 billion by 2005. In the firm?s
April 2003 report, the top 50 medical device companies spent roughly
$3.7 billion on R&D in 2002, an increase from $3.4 billion spent the
year before. Overall in 2002, medical device companies spent roughly
8.8% of their revenues on R&D. As the U.S. market grows, it is also
becoming more aware of cost.

In a recent study from The Freedonia Group, U.S. demand for disposable
medical supplies will increase 5.6% annually to more than $79 billion
by 2007. Intravascular, catheterization and related products will
provide the best growth opportunities, with demand increasing 7.2%
annually through 2007.

Unfortunately for startup medical device companies, venture capital
investment began to dry up in 2001. Along with decreasing VC
investment came decreasing corporate R&D investment as the economy
went into recession. The 2001 recession, combined with economic
uncertainty and closure of the IPO market, resulted in pervasive risk
aversion in the healthcare industry.

According to venture capital research firm VentureOne and Venture
Reporter, during the past few years healthcare and medical device VC
investment has decreased dramatically. Despite these cut-backs,
medical device VC investment in 2002 was $1.5 billion. As compared to
either healthcare, IT or the biotech sectors, VC investment in the
medical device segment has shown much less fluctuation. Analyzed over
the long term, medical device VC investment is three times higher now
than in the mid 1990s..."


FYI - At Allergan

Scroll down to:   Discontinued Operations
http://biz.yahoo.com/e/040305/agn10-k.html

..."The spin-off was effected by contributing our optical medical
device business to a newly formed subsidiary, Advanced Medical Optics,
Inc., and issuing a dividend of Advanced Medical Optics' common stock
to our stockholders. The common stock of Advanced Medical Optics began
trading publicly on the New York Stock Exchange on July 1, 2002 under
the symbol "AVO." As a result of the spin-off, we continue to own and
operate our specialty pharmaceutical business, and Advanced Medical
Optics owns and operates what was formerly our optical medical device
business. We have no ownership interest in Advanced Medical Optics.
Our consolidated financial statements and related notes contained
herein have been recast to reflect the financial position, results of
operations and cash flows of Advanced Medical Optics as a discontinued
operation.

We did not account for our ophthalmic surgical and contact lens care
businesses as a separate legal entity. Therefore, the following
selected financial data for our discontinued operations is presented
for informational purposes only and does not necessarily reflect what
the net sales or earnings would have been had the businesses operated
as a stand-alone entity. The financial information for our
discontinued operations includes allocations of certain of our
expenses to those operations. These amounts have been allocated to our
discontinued operations on the basis that is considered by management
to reflect most fairly or reasonably the utilization of the services
provided to, or the benefit obtained by, those operations. See Note 2,
"Discontinued Operations," in the notes to the consolidated financial
statements listed under Item 15(a) of Part IV of this report.

Effective with the third quarter of our 2002 fiscal year, we no longer
include the results of operations and cash flows of our discontinued
optical medical device business in our consolidated financial
statements..."



Helpful links to bookmark:

Medical Equipment and Pharmaceutical Manufacturers
http://mtdesk.com/mfg.shtml

Medical Device Companies
http://www.business.com/directory/healthcare/medical_devices/


~~Cynthia


Search strategy so far:
"medical device" "acquired by"


PS:  Cancel the other question.... no need to pay to ask for me... 
you'll only be charged the 50 cent listing fee.

---

Clarification of Question by 11boomer-ga on 20 Feb 2005 10:18 PST

you're on the right track. Medical device companies that sold in the
last 12 months, especially ones involving Allergan if you have any.
Annual Gross Income and sales price needed. you're the best, by the
way, I'll have a tequila!

---

Request for Question Clarification by cynthia-ga on 20 Feb 2005 12:11 PST

Nothing on Allergan yet, but I have a surprise.  I checked that link
more carefully and there were a few more acquisitions.  While getting
information on the first one, below, I ran into the MOTHERLOAD of
Medical Device "Merger, Acquisitions and Strategic Transaction"
information sources.

Please select 2, 3, or 4 Acquisitions, at the most, that you want me
to research for this question, I don't know how long it'll take me to
run down the numbers, sorry, it depends how user friendly the web
sites are.. or alternately, you can increase your price for this
Question for more Companies, or ask new Questions at your leisure.

I'd like to do Medtronics (which includes Physio-Control) for you,
this document says it was acquired by the Stryker Corporation in
August of 2004 (seemed more recent, or maybe there was a blackout). 
If it proves difficult I'll let you know so you can choose another.


Here's the link for the Mother Load:


The Strategic Healthcare M&A Report
A Bi-Monthly Review of Merger, Acquisition and Strategic Transactions
in the Healthcare Industry
http://waldenmed.com/newsletters/strategic-healthcare-report-dec-04.pdf

There's hundreds to select from. Please note that the one I have
linked to (Dec 04) is not the only one.  Look at the URL.  You can
keep the same format and change the date (dec-04) to get any month &
year (jan-05, etc). Waaaay too many for me to choose from, so I
thought I'd show you the source and let you decide.


Here's what I had before I hit the Mother Load:

*************************************************************************************

Abbott acquires Spine Next SA
http://www.medical-devices-faraday.com/news_industry.html (same source
link for the rest below)
..."Abbott Laboratories has acquired Spine Next SA of Bordeaux,
France, a privately-owned manufacturer of orthopaedic spinal implant
devices. In 2003 Abbott had already acquired Spinal Concepts.
Approximately 400,000 back surgery operations were performed in the
USA in 2004 and more than 60% involved prosthesis of some kind..."
Advanced Materials Processes, Vol.163 No.1, Jan.2005. p.58

ABBOTT ACQUIRES SPINE NEXT, S.A., A MANUFACTURER OF NON-FUSION SPINAL
IMPLANT DEVICES
http://www.abbott.com/news/press_release.cfm?id=843
..."Under terms of the agreement, Abbott acquired all of the equity of
Spine Next for approximately $60 million in cash plus additional
milestone payments upon achievement of future targets. One-time
charges are expected in the fourth quarter of 2004, primarily for
in-process research and development, as included in Abbott?s guidance
for one-time charges in its news release on third quarter earnings,
issued October 14, 2004..."


*************************************************************************************

Stryker completes acquisition of SpineCore
..."SpineCore Inc. (Summit, NJ, USA), producer of artificial lumber
and cervical discs, has been acquired by Stryker Corp. (Kalamazoo, MI,
USA). Stryker is a manufacturer of medical devices..."
Biomedical Materials. Oct.2004. pp.8-9.


*************************************************************************************

Encore Medical buys BioHorizons Implant Systems
http://www.minivodkaguy.com/Cuervo1800New.jpg  whoops
..."Manufacturer of dental implants and oral reconstructive products,
BioHorizons Implant Systems Inc. (Alabama, USA), is being acquired by
Encore Medical Corp, a US orthopaedic device company. BioHorizons will
become a subsidiary of Encore..."
Biomedical Materials. July 2004. pp.6-7.


*************************************************************************************

Smith & Nephew buy UK hip resurfacing business
..."Midland Medical Technologies (MMT: Birmingham, UK) has been
acquired by Smith & Nephew. The company's principal product is
Birmingham Hip Resurfacing (BHR) involving the replacement of the
articular surfaces of the femur and acetabulum, and preserving the
femoral head. 27,000 patients have been treated using the procedure
over the past 7 years. MMT is to be integrated into the Smith & Nephew
Orthopaedics Reconstruction division (Memphis, TN, USA)..."
Biomedical Materials. May 2004. pp.5-6.


*************************************************************************************

Biomet acquires Interpore
http://www.tequila-shots.com/tequilahistory.html <~~~ typo
..."Biomet has agreed to purchase all the outstanding common stock of
Interpore International Inc. Interpore has a wide portfolio of spinal
products, plus good research and development facilities. The take-over
will give Biomet revenues of US$200M and a salesforce of over 400..."
Biomedical Materials. May 2004. pp.8-9.


*************************************************************************************

Edwards Lifesciences buys PVT
..."Edwards Lifesciences Corp., a US heart valve manufacturer, is to
acquire Percutaneous Valve Technologies Inc. (PVT), a medical
technology company based in Fort Lee (NJ, USA) with a subsidiary in
Israel. PVT produces a balloon-expandable stent technology integrated
with a percutaneously delivered tissue heart valve. The market for
catheter-based valve repair and replacement products is forecast to
top US$1bn by 2014. Further details are given..."
Biomedical Materials. Feb.2004. pp.5-6.


*************************************************************************************

COMPANY TO WATCH:

Boston Scientific acquires option to buy Cameron Health
http://html.nbc5.com/sh/quizine/833938/833938-1.html  my bad
..."Boston Scientific has made an equity investment in Cameron Health
(CA, USA), manufacturer of a leadless implantable cardioverter
defribulator (ICD) implanted in subcutaneous tissue. The investment
has an exclusive option to acquire the company..."
Biomedical Materials. April 2004. pp.7-8.


*************************************************************************************


Let me know, take your time.  I'm doing laundry, no work till Tuesday
night, but don't get TOO distracted at the Tequila Trivia site.  ;-)


~~Cynthia

---

Clarification of Question by 11boomer-ga on 22 Feb 2005 06:10 PST

Mother load is right. In the Nov issue there was one I'd like you to research:
Sybron Dental Specialties bought Innova LifeSciences 10/15/04.  In the
Dec issue there was one: Kyorin bought Activx 12/3/04, and the one you
listed before the mother load:
Encore Medical buys BioHorizons Implant Systems

..."Manufacturer of dental implants and oral reconstructive products,
BioHorizons Implant Systems Inc. (Alabama, USA), is being acquired by
Encore Medical Corp, a US orthopaedic device company. BioHorizons will
become a subsidiary of Encore..."
Biomedical Materials. July 2004. pp.6-7.

I'll tip $50 each for details on terms of sale (sales price, gross
annual income of company bought, future predictions of income, etc.)

P.S. Got 6 out of 10 on the tequila test (should have been 8)

---

Request for Question Clarification by cynthia-ga on 22 Feb 2005 09:14 PST

TUESDAY AM

******************************************************************************

Innova LifeSciences Corporation
http://www.innovalife.com/
http://www.innovalife.com/investors/

Sybron Dental Specialties, Inc. Succeeds in Offer for Innova
LifeSciences Corporation
http://investors.sybrondental.com/phoenix.zhtml?c=124926&p=irol-newsArticle&ID=631178&highlight=
TORONTO--(BUSINESS WIRE)--Oct. 15, 2004--Sybron Dental Specialties,
Inc. (NYSE:SYD) ("Sybron") today announced that it has been successful
in the offer (the "Offer") made by its indirect wholly-owned
subsidiary, Sybron Canada Limited, to acquire Innova LifeSciences
Corporation ("Innova"). The Offer was made at a price of $1.4106 in
cash per common share. 39,363,764 of the common shares of Innova,
being approximately 94.18% of the issued and outstanding common shares
on a fully diluted basis, have been deposited to the Offer.

The sale amount is reported to be about $60M, here:
http://waldenmed.com/newsletters/strategic-healthcare-report-dec-04.pdf

Q1 2004 Financial Report
http://www.innovalife.com/investors/pdf/2004_q1.pdf
Q1 2004 Sales = $5,882,500
..."During the first quarter of 2004, Innova LifeSciences Corporation
achieved all-time records for
both sales and net income. Strong increases in implant unit sales
volumes translated into
higher revenue and net income in spite of the lower US dollar and the
Company?s continuing
expansion of its marketing programs. Revenue increased 10% on volume
increases of 18%, with
the decline in the value of the US dollar suppressing the Company?s
reported revenues...."

Q2 2004 Financial Report
http://www.innovalife.com/investors/pdf/2004_q2.pdf
Q2 2004 Sales = $6,065,916  
YEAR TO DATE =  $11,948,416

Principals are listed here:
http://www.hoovers.com/innova-lifesciences/--ID__112733--/free-co-factsheet.xhtml
Chairman, President, and CEO:   Michael A. Kehoe 
SVP Operations:   Keith L. Carter
CFO:   Michael J. Nealon

SYBRON 2004 ANNUAL REPORT:
http://media.corporate-ir.net/media_files/irol/12/124926/reports/2004SDSAnnualReport.pdf
This is a great report.  Use the search finction and enter INNOVA and
select 'whole words only.'  Get a feel for it at the link below:

This page recaps the report:

Sybron Dental Specialties, Inc. Reports 23% Increase in Earnings per Share
http://investors.sybrondental.com/phoenix.zhtml?c=124926&p=irol-newsArticle&ID=666030&highlight=
[Note Contact Info at the bottom of this link, this person was
undoubtedly a principal in the transaction.]
ORANGE, Calif., Jan. 24 /PRNewswire-FirstCall/ -- Sybron Dental
Specialties, Inc. (NYSE: SYD), a leading manufacturer of a broad range
of value-added products for the professional dental market and the
specialty markets of orthodontics, endodontics, implants and infection
prevention, announced today its financial results for its first fiscal
quarter ended December 31, 2004.

FIRST Quarter Results

Net sales for the first quarter of fiscal 2005 totaled $149.0 million,
an increase of 13.0% over the $131.9 million in net sales in the prior
year period. Sybron's internal net sales, which exclude currency
fluctuations and the impact of acquisitions made in the past twelve
months, grew 6.7% in the first quarter. The Company's consumable
products, which represented approximately 97.5% of total net sales in
the first quarter of fiscal 2005, had an internal net sales growth
rate of 8.2%.

Net income for the first quarter of fiscal 2005 was $15.0 million, or
$0.37 per diluted share, compared with net income of $11.9 million, or
$0.30 per diluted share, in the same period of the previous year.
Diluted earnings per share increased by 23% over the prior year
period.

In the first quarter of fiscal 2005, Sybron generated $16.4 million in
free cash flow, defined as cash flows from operating activities of
$19.8 million minus capital expenditures of $3.4 million. This
compares with free cash flow of $17.6 million in the same period of
the previous year (cash flows from operating activities of $20.3
million minus capital expenditures of $2.7 million).

"We had an excellent start to the fiscal year driven by a strong
response to our recently introduced products," said Floyd W. Pickrell,
Jr., Chief Executive Officer of Sybron Dental Specialties. "We believe
we are continuing to increase our market share in orthodontics, and we
are pleased with the strong internal growth of our consumable
professional dental products. We are also seeing the benefits of our
recent facility rationalization efforts, which, along with more
favorable foreign currency exchange rates, produced an increase in
gross margin of almost three percentage points over the prior year."


http://media.corporate-ir.net/media_files/irol/12/124926/reports/2004SDSAnnualReport.pdf


******************************************************************************

Activx
http://www.activx.com/

ActivX Biosciences Announces Closing of Acquisition by Kyorin
Pharmaceutical Co., Ltd.
http://www.activx.com/press/KyorinAcq.htm
..."La Jolla, CA; February 2, 2005 ? ActivX Biosciences, Inc., a
biotechnology company developing advanced proteomic technologies for
drug discovery and development, has announced the formal completion of
its acquisition by Tokyo-based Kyorin Pharmaceutical Co., Ltd. (TSE:
4560). The acquisition agreement was signed on December 1, 2004 for an
aggregate price of $21,000,000. With the completion of the
transaction, ActivX survives as a wholly-owned subsidiary and will
serve as Kyorin?s drug discovery and development center in the U.S..."

Sales price is reported as $24M here:
http://waldenmed.com/newsletters/strategic-healthcare-report-jan-05.pdf

I am unable to locate the Annual Reports, yet, so I have provided a
link to HOOVERS:

http://www.hoovers.com/activx/--ID__129897--/free-co-factsheet.xhtml
SALES:  $4.3 Million est.  This is the only Annual Sales figure I caould locate.

Here too:
http://finance.yahoo.com/search?type=&s=ActivX&r=&=Search

ActivX Key People
CEO	James A. (Jim) Schoeneck
President and Chief Research and Development Officer	John W. Kozarich
EVP and CFO	J. C. MacRae

http://www.kyorin-pharm.co.jp/eg/index.html
INVESTOR INFO:  http://www.kyorin-pharm.co.jp/eg/ir/index.html
FINANCIAL REPORTS:  http://www.kyorin-pharm.co.jp/eg/ir/event.html
ANNOUNCEMENT OF ACQUISITION:  http://www.kyorin-pharm.co.jp/eg/ir/ActivX.pdf
Aggregate price is listed here as $21,000,000 

Principals are listed there as well.
..."Kyorin Pharmaceutical Co., Ltd. (Tokyo; President: Ikuo Ogihara)
(?Kyorin?) agreed on December 1, 2004 with ActivX Biosciences, Inc.
(California; C.E.O.: James A. Schoeneck) (?ActivX?) that Kyorin will
acquire ActivX. Upon the closing of the transaction, a U.S. subsidiary
of Kyorin established to effectuate the acquisition will be merged
with and into ActivX, and ActivX will survive the merger as a wholly
owned subsidiary of Kyorin...."

OUTLOOK - News Release Feb 9, 2005:

ActivX Biosciences Announces Expansion of Strategic Collaboration
Agreement with Pfizer Inc. with Multiple Discovery and Developmental
Stage Projects
http://money.cnn.com/services/tickerheadlines/prn/law077.P2.02082005213245.01309.htm
..."Pfizer Inc. and ActivX Biosciences, Inc., a wholly-owned
subsidiary of Tokyo-based Kyorin Pharmaceutical Co., Ltd. , announced
today they have entered into a strategic collaborative agreement
encompassing multiple projects ranging from discovery to developmental
stage programs across multiple research sites of Pfizer's Global
Research and Development organization..."


******************************************************************************

BioHorizons Implant Systems
http://www.biohorizons.com/

Annual Reports not at the web site, nothing available at Hoovers.

Based in Birmingham, Alabama, BioHorizons had sales of approximately
$16 million in 2003.
		
Encore Medical to Acquire BioHorizons Implant Systems, Inc.
http://ir.thomsonfn.com/InvestorRelations/PubNewsStory.aspx?partner=7229&storyId=114367
..."Under the terms of the agreement, Encore will acquire all of the
outstanding common stock of BioHorizons for $5.2 million in cash and
approximately 2.6 million shares of Encore common stock, representing
a total current acquisition value of approximately $26 million. As a
result, the current shareholders of BioHorizons will own approximately
6% of the outstanding stock of Encore after the transaction. There are
also up to $10 million in future milestone payments that could be
earned by, and paid to, the stockholders of BioHorizons, based on the
performance of the acquired company through the year 2006. The merger
is subject to the satisfaction of a number of conditions, including
the filing and effectiveness of a registration statement with the
Securities and Exchange Commission. The transaction is still subject
to the approval of the shareholders of BioHorizons. Encore
stockholders are not required to vote on or consent to the merger.
BioHorizons will merge with and into a merger subsidiary of Encore.
Encore expects the transaction to close during the third quarter of
2004. It is expected that the acquisition will contribute
approximately $10 million in product sales during the remainder of
2004 after the closing of the transaction. Encore expects the
acquisition to be accretive in 2004 and thereafter..."
Contact information (Encore) is at the bottom of that link.

Encore Investors Info
http://www.encoremed.com/company/investors_info.htm

Encore Fact Sheet
http://www.encoremed.com/pdf/encorefactsheet.pdf

Cool feature, choose a report to view:
http://ir.thomsonfn.com/InvestorRelations/KeyRatios.aspx?partner=7229

SEC FILINGS:
http://phx.corporate-ir.net/phoenix.zhtml?c=88864&p=irol-sec

KEY PEOPLE:
Kenneth W. Davidson, CEO & President
William W. Burke, EVP-CFO
Harry L. Zimmerman, EVP-General Counsel


******************************************************************************
******************************************************************************

AND JUST BECAUSE I FOUND THEM:

The Next Home Run Stock
http://www.fool.com/news/commentary/2005/commentary05020202.htm?source=eptyholnk303100&logvisit=y&npu=y&bounce=y&bounce2=y

I found that link here:
Biotechnology Industry News - http://biz.yahoo.com/n/y/y0005.html?id=18665448


******************************************************************************


I'm disappointed I was not able to find more info on a couple of
those.  Go ahead and pick a couple more.  I have to sleep today (my
schedule is totally backwards, then bartend at 7pm Pacific.  I get
home around 2:30am, wide awake.  I'll keep posting in the
clarification area till you decide I'm done, then I'll post in the
Answer box for payment.


~~Cynthia

---

Request for Question Clarification by cynthia-ga on 22 Feb 2005 09:16 PST

A couple of the links for Innova are messed up, you'll need to correct
them by removing the Q1 and Q2 from the end, after the .pdf...   My
bad, sorry.

~~Cyn

---

Request for Question Clarification by cynthia-ga on 28 Feb 2005 04:09 PST

11boomer,

I assume you don't need more info...  I'll wait a couple more days to
see if you reply before posting in the Answer box.

~~Cynthia

---

Clarification of Question by 11boomer-ga on 28 Feb 2005 05:26 PST

Can you research Invitrogen's purchase of DNA 10/28/04, and Memry's
purchase of Putnam on 11/09/04? Thanks a million, Jim

Hi Jim,

I'll start with the last, first, so you have something new to read...

**********************************************************************
**********************************************************************

INVITROGEN and DNA RESEARCH INNOVATIONS

**********************************************************************

DNA Research Innovations Ltd.
Sittingbourne Research Centre
Kent, ME9 8PX UK
Tel: +44(0) 1795 411 114 
Fax: +44(0) 1795 411 115 
Email: commercial@dri-dna.co.uk

Acquisition of DNA Research Innovations, Ltd.
http://www.financials.com/c/info/story.cfm?storynum=1114513
According to the terms of the deal, Invitrogen paid
$35 million in cash, and may make contingent payments of up to $30
million based upon the completion of certain R & D milestones. The
deal is not expected to change Invitrogen's guidance for the fourth
quarter of 2004.


DNA's Financial Reports are not easily found, maybe it's because it
was privately held before the acquisition.  Here's Invitrogen's.  All
your numbers are visible and easily found here:

Last 4 quarters
http://finance.yahoo.com/q/is?s=IVGN

Last 3 Calendar years:
http://finance.yahoo.com/q/is?s=IVGN&annual

Key Statistics
http://finance.yahoo.com/q/ks?s=IVGN

Invitrogen Corp (IVGN)
http://finance.myepath.com/q?s=IVGN&d=t

Investor Kits
http://phx.corporate-ir.net/phoenix.zhtml?c=61498&p=irol-proxy

Quarterly's through Q3 2004:
http://phx.corporate-ir.net/phoenix.zhtml?c=61498&p=irol-reportsOther

Annual Reports through 2003:
http://phx.corporate-ir.net/phoenix.zhtml?c=61498&p=irol-reportsAnnual

SEC Filings:
http://phx.corporate-ir.net/phoenix.zhtml?c=61498&p=irol-sec


**********************************************************************

MEMRY and PUTNAM PLASTICS

**********************************************************************

Putnam's financials are not easily found on their web site either.

Putnam Plastics
http://www.putnamplastics.com/

Here's what is available:

Form 8-K for MEMRY CORP - November 12, 2004

Acquisition of Putnam Plastics Corporation.
http://biz.yahoo.com/e/041112/mry8-k.html
..."The Company paid (or, as noted below, will pay) a purchase price,
subject to certain post closing adjustments for working capital and
for a tax gross-up, consisting of $17.0 million in cash, 2,857,143
shares of the Company's common stock, and $2.5 million in deferred
payments. The deferred payments are non-interest bearing and are
required to be paid in three equal annual  installments beginning
November 9, 2005..."


More figures at this link:
http://biz.yahoo.com/prnews/050209/flw009_1.html
..."Putnam's revenue for the period ended December 31, 2004 was
$1,577,000. Net income was $406,000 or $0.01 per basic and diluted
share compared with net income of $228,000 or $0.01 per basic and
diluted share in the comparable period last year.

For the first six months of the fiscal year 2005 that ends June 30,
2005, revenue was $18,989,000 compared with revenue of $16,263,000 in
the first half of fiscal 2004, an increase of $2,726,000 or 16.8%. Net
income for Memry in the first six months was $1,110,000 or $0.04 per
basic and diluted share compared with net income of $725,000 or $0.03
per basic and diluted share in the first half of fiscal year 2004.

James G. Binch, CEO of Memry, said, "The closing of the Putnam
Plastics acquisition in November has added a valuable new dimension to
Memry strategically as well as financially. Putnam's contribution to
revenue during the second quarter was $1,577,000. By product line,
polymers represented 16% of Memry's consolidated sales this quarter.
We expect a full quarter of Putnam's contributions in our third fiscal
quarter will provide even stronger results..."


Here is Memry's available info:

Last 4 Quarters
http://finance.yahoo.com/q/is?s=MRY

Last 3 Calendar Years
http://finance.yahoo.com/q/is?s=MRY&annual

Key Statistics
http://finance.yahoo.com/q/ks?s=MRY

Key SEC Filings for Memry Cp
http://www.hawkmicrocaps.com/page.asp?page_id=31

Note the contact information on the bottom:
http://www.financials.com/info/story.cfm?storynum=1215720

This is the Virtual Investor Kit for Memry Corporation.
http://www.hawkassociates.com/memry/kit.htm

Memry 's Company Profile for Investors
http://www.hawkassociates.com/memry/profile.pdf

2004 Annual Report:
http://www.hawkassociates.com/memry/annual.pdf

SEC Filings
http://www.hawkassociates.com/memry/sec.htm

Investor Relations Services
http://www.hawkassociates.com/investorrelations/

Investor FAQ's
http://www.hawkassociates.com/memry/faq.htm


**********************************************************************

INNOVA and SABRON

**********************************************************************

Innova LifeSciences Corporation
http://www.innovalife.com/
http://www.innovalife.com/investors/

Sybron Dental Specialties, Inc. Succeeds in Offer for Innova
LifeSciences Corporation
http://investors.sybrondental.com/phoenix.zhtml?c=124926&p=irol-newsArticle&ID=631178&highlight=
TORONTO--(BUSINESS WIRE)--Oct. 15, 2004--Sybron Dental Specialties,
Inc. (NYSE:SYD) ("Sybron") today announced that it has been successful
in the offer (the "Offer") made by its indirect wholly-owned
subsidiary, Sybron Canada Limited, to acquire Innova LifeSciences
Corporation ("Innova"). The Offer was made at a price of $1.4106 in
cash per common share. 39,363,764 of the common shares of Innova,
being approximately 94.18% of the issued and outstanding common shares
on a fully diluted basis, have been deposited to the Offer.

The sale amount is reported to be about $60M, here:
http://waldenmed.com/newsletters/strategic-healthcare-report-dec-04.pdf 

Q1 2004 Financial Report
http://www.innovalife.com/investors/pdf/2004_q1.pdf
Q1 2004 Sales = $5,882,500
..."During the first quarter of 2004, Innova LifeSciences Corporation
achieved all-time records for both sales and net income. Strong
increases in implant unit sales volumes translated into higher revenue
and net income in spite of the lower US dollar and the Company?s
continuing expansion of its marketing programs. Revenue increased 10%
on volume increases of 18%, with the decline in the value of the US
dollar suppressing the Company?s reported revenues...."

Q2 2004 Financial Report
http://www.innovalife.com/investors/pdf/2004_q2.pdf
Q2 2004 Sales = $6,065,916  
YEAR TO DATE =  $11,948,416

Principals are listed here:
http://www.hoovers.com/innova-lifesciences/--ID__112733--/free-co-factsheet.xhtml
Chairman, President, and CEO:   Michael A. Kehoe 
SVP Operations:   Keith L. Carter
CFO:   Michael J. Nealon

SYBRON 2004 ANNUAL REPORT:
http://media.corporate-ir.net/media_files/irol/12/124926/reports/2004SDSAnnualReport.pdf
This is a great report.  Use the search finction and enter INNOVA and
select 'whole words only.'  Get a feel for it at the link below:

This page recaps the report:

Sybron Dental Specialties, Inc. Reports 23% Increase in Earnings per Share
http://investors.sybrondental.com/phoenix.zhtml?c=124926&p=irol-newsArticle&ID=666030&highlight=
[Note Contact Info at the bottom of this link, this person was
undoubtedly a principal in the transaction.]
ORANGE, Calif., Jan. 24 /PRNewswire-FirstCall/ -- Sybron Dental
Specialties, Inc. (NYSE: SYD), a leading manufacturer of a broad range
of value-added products for the professional dental market and the
specialty markets of orthodontics, endodontics, implants and infection
prevention, announced today its financial results for its first fiscal
quarter ended December 31, 2004.

FIRST Quarter Results

Net sales for the first quarter of fiscal 2005 totaled $149.0 million,
an increase of 13.0% over the $131.9 million in net sales in the prior
year period. Sybron's internal net sales, which exclude currency
fluctuations and the impact of acquisitions made in the past twelve
months, grew 6.7% in the first quarter. The Company's consumable
products, which represented approximately 97.5% of total net sales in
the first quarter of fiscal 2005, had an internal net sales growth
rate of 8.2%.

Net income for the first quarter of fiscal 2005 was $15.0 million, or
$0.37 per diluted share, compared with net income of $11.9 million, or
$0.30 per diluted share, in the same period of the previous year.
Diluted earnings per share increased by 23% over the prior year
period.

In the first quarter of fiscal 2005, Sybron generated $16.4 million in
free cash flow, defined as cash flows from operating activities of
$19.8 million minus capital expenditures of $3.4 million. This
compares with free cash flow of $17.6 million in the same period of
the previous year (cash flows from operating activities of $20.3
million minus capital expenditures of $2.7 million).

"We had an excellent start to the fiscal year driven by a strong
response to our recently introduced products," said Floyd W. Pickrell,
Jr., Chief Executive Officer of Sybron Dental Specialties. "We believe
we are continuing to increase our market share in orthodontics, and we
are pleased with the strong internal growth of our consumable
professional dental products. We are also seeing the benefits of our
recent facility rationalization efforts, which, along with more
favorable foreign currency exchange rates, produced an increase in
gross margin of almost three percentage points over the prior year."


http://media.corporate-ir.net/media_files/irol/12/124926/reports/2004SDSAnnualReport.pdf


**********************************************************************

ACTIVX and KYORIN

**********************************************************************

Activx
http://www.activx.com/

ActivX Biosciences Announces Closing of Acquisition by Kyorin
Pharmaceutical Co., Ltd.
http://www.activx.com/press/KyorinAcq.htm
..."La Jolla, CA; February 2, 2005 ? ActivX Biosciences, Inc., a
biotechnology company developing advanced proteomic technologies for
drug discovery and development, has announced the formal completion of
its acquisition by Tokyo-based Kyorin Pharmaceutical Co., Ltd. (TSE:
4560). The acquisition agreement was signed on December 1, 2004 for an
aggregate price of $21,000,000. With the completion of the
transaction, ActivX survives as a wholly-owned subsidiary and will
serve as Kyorin?s drug discovery and development center in the U.S..."

Sales price is reported as $24M here:
http://waldenmed.com/newsletters/strategic-healthcare-report-jan-05.pdf 

I am unable to locate the Annual Reports, yet, so I have provided a
link to HOOVERS:

http://www.hoovers.com/activx/--ID__129897--/free-co-factsheet.xhtml
SALES:  $4.3 Million est.  This is the only Annual Sales figure I caould locate.

Here too:
http://finance.yahoo.com/search?type=&s=ActivX&r=&=Search

ActivX Key People
CEO	James A. (Jim) Schoeneck
President and Chief Research and Development Officer	John W. Kozarich
EVP and CFO	J. C. MacRae

http://www.kyorin-pharm.co.jp/eg/index.html
INVESTOR INFO:  http://www.kyorin-pharm.co.jp/eg/ir/index.html
FINANCIAL REPORTS:  http://www.kyorin-pharm.co.jp/eg/ir/event.html
ANNOUNCEMENT OF ACQUISITION:  http://www.kyorin-pharm.co.jp/eg/ir/ActivX.pdf 
Aggregate price is listed here as $21,000,000 

Principals are listed there as well.
..."Kyorin Pharmaceutical Co., Ltd. (Tokyo; President: Ikuo Ogihara)
(?Kyorin?) agreed on December 1, 2004 with ActivX Biosciences, Inc.
(California; C.E.O.: James A. Schoeneck) (?ActivX?) that Kyorin will
acquire ActivX. Upon the closing of the transaction, a U.S. subsidiary
of Kyorin established to effectuate the acquisition will be merged
with and into ActivX, and ActivX will survive the merger as a wholly
owned subsidiary of Kyorin...."

OUTLOOK - News Release Feb 9, 2005:

ActivX Biosciences Announces Expansion of Strategic Collaboration
Agreement with Pfizer Inc. with Multiple Discovery and Developmental
Stage Projects
http://money.cnn.com/services/tickerheadlines/prn/law077.P2.02082005213245.01309.htm
..."Pfizer Inc. and ActivX Biosciences, Inc., a wholly-owned
subsidiary of Tokyo-based Kyorin Pharmaceutical Co., Ltd. , announced
today they have entered into a strategic collaborative agreement
encompassing multiple projects ranging from discovery to developmental
stage programs across multiple research sites of Pfizer's Global
Research and Development organization..."


**********************************************************************

ENCORE and BIOHORIZONS

**********************************************************************

BioHorizons Implant Systems
http://www.biohorizons.com/

Annual Reports not at the web site, nothing available at Hoovers.

Based in Birmingham, Alabama, BioHorizons had sales of approximately
$16 million in 2003.
		
Encore Medical to Acquire BioHorizons Implant Systems, Inc.
http://ir.thomsonfn.com/InvestorRelations/PubNewsStory.aspx?partner=7229&storyId=114367
..."Under the terms of the agreement, Encore will acquire all of the
outstanding common stock of BioHorizons for $5.2 million in cash and
approximately 2.6 million shares of Encore common stock, representing
a total current acquisition value of approximately $26 million. As a
result, the current shareholders of BioHorizons will own approximately
6% of the outstanding stock of Encore after the transaction. There are
also up to $10 million in future milestone payments that could be
earned by, and paid to, the stockholders of BioHorizons, based on the
performance of the acquired company through the year 2006. The merger
is subject to the satisfaction of a number of conditions, including
the filing and effectiveness of a registration statement with the
Securities and Exchange Commission. The transaction is still subject
to the approval of the shareholders of BioHorizons. Encore
stockholders are not required to vote on or consent to the merger.
BioHorizons will merge with and into a merger subsidiary of Encore.
Encore expects the transaction to close during the third quarter of
2004. It is expected that the acquisition will contribute
approximately $10 million in product sales during the remainder of
2004 after the closing of the transaction. Encore expects the
acquisition to be accretive in 2004 and thereafter..."
Contact information (Encore) is at the bottom of that link.

Encore Investors Info
http://www.encoremed.com/company/investors_info.htm

Encore Fact Sheet
http://www.encoremed.com/pdf/encorefactsheet.pdf 

Cool feature, choose a report to view:
http://ir.thomsonfn.com/InvestorRelations/KeyRatios.aspx?partner=7229

SEC FILINGS:
http://phx.corporate-ir.net/phoenix.zhtml?c=88864&p=irol-sec

KEY PEOPLE:
Kenneth W. Davidson, CEO & President
William W. Burke, EVP-CFO
Harry L. Zimmerman, EVP-General Counsel

**********************************************************************
**********************************************************************

And here's info for Medtronics in Redmond WA, where my friend works:

MEDTRONICS
http://www.medtronic.com/

Medtronic Inc (MDT) Key Statistics
http://finance.yahoo.com/q/ks?s=MDT

Overview
http://phx.corporate-ir.net/phoenix.zhtml?c=76126&p=irol-irhome

Medtronics 2004 Annual Report
http://www.medtronic.com/annual_reports/annual04/fin.pdf

Last 4 Quarterly Reports
http://phx.corporate-ir.net/phoenix.zhtml?c=76126&p=irol-reportsother

Medtronics SEC FIlings
http://phx.corporate-ir.net/phoenix.zhtml?c=76126&p=irol-sec

Stock Chart
http://phx.corporate-ir.net/phoenix.zhtml?c=76126&p=irol-stockchart

Executive Management Team
http://wwwp.medtronic.com/Newsroom/ExecutiveManagement.do?lang=en_US


**********************************************************************

OTHER USEFUL and INTERESTING LINKS

**********************************************************************

The Strategic Healthcare M&A Report - A Bi-Monthly Review of Merger,
Acquisition and Strategic Transactions in the Healthcare Industry
http://waldenmed.com/newsletters/strategic-healthcare-report-dec-04.pdf 

QUARTERLY INDUSTRY REPORTS by Burrill and Company
http://www.burrillandco.com/burrill/pr_1105471928

The Next Home Run Stock
http://www.fool.com/news/commentary/2005/commentary05020202.htm?source=eptyholnk303100&logvisit=y&npu=y&bounce=y&bounce2=y

I found that link here:
Biotechnology Industry News - http://biz.yahoo.com/n/y/y0005.html?id=18665448

Medical Equipment and Pharmaceutical Manufacturers
http://mtdesk.com/mfg.shtml

Medical Device Companies
http://www.business.com/directory/healthcare/medical_devices/


**********************************************************************

Thanks for the opportunity to work for you again!  Be sure to let me
know if there's anything else I can do for you.


~~Cynthia

Veri nice work